

22 *Correspondence to:

- 23 Siim Pauklin PhD
- 24 Group leader and CRUK Career Development Fellow
- 25 Botnar Research Centre, Nuffield Department of Orthopaedics, Rheumatology and
- ²⁶Musculoskeletal Sciences, University of Oxford, Headington, Oxford OX3 7LD, UK.
- 27 Tel: +44 (0)-1865226492
- ²⁸Email: siim.pauklin@ndorms.ox.ac.uk
- 29
- 30 Jinguo Xu, MD, PhD
- ³¹Associate Professor
- 32 Department of Cardiovascular Surgery, First Affiliated Hospital of Anhui Medical
- ³³University, Hefei, Anhui, 230022, China
- 34 Tel: +86 (551)-65908735
- ³⁵Email: xujinguo@ahmu.edu.cn
-
- 37 Yining Yang MD, PhD
- 38 Professor
- ³⁹Department of Cardiology, People's Hospital of Xinjiang Uygur Autonomous Region,
- ⁴⁰Urumqi, Xinjiang Uygur Autonomous Region, 830000, China.
- ⁴¹Xinjiang Key Laboratory of Cardiovascular Homeostasis and Regeneration Research,
- 42 Urumqi, Xinjiang Uygur Autonomous Region, 830000, China.
- ⁴³Tel:+86 (0991)-960200
- ⁴⁴Email: yangyn5126@xjrmyy.com

45

- 46 Yuliang Feng MD, PhD
- ⁴⁷Associate Professor
- ⁴⁸Department of Pharmacology, Joint Laboratory of Guangdong-Hong Kong
- 49 Universities for Vascular Homeostasis and Diseases, School of Medicine, Southern
- ⁵⁰University of Science and Technology, Shenzhen, Guangdong, 518055, China.
- 51 Tel: + 86 (755)-88012564
- ⁵²Email: fengyl@sustech.edu.cn

53

Abstract

- 75 genetic links between eGFR and CVDs, potentially guiding the development of novel
- 76 therapeutic strategies and improving the clinical management of these conditions.

77

⁷⁸**Keywords**

- 79 Estimated glomerular filtration rate, Cardiovascular disease, Shared genetic
- 80 architectures, GWAS

⁸²**Introduction**

83 Cardiovascular diseases (CVDs) are the leading cause of mortality and disability 84 globally, accounting for one-third of all deaths.¹ The American Heart Association 85 anticipates that by 2035, the economic impact of CVDs will escalate to approximately 86 \$1.1 trillion. Among the diverse risk factors, chronic kidney disease (CKD) is 87 particularly significant, as it exacerbates heart disease.² CKD leads to an increased 88 production of reactive oxygen species (ROS) through oxidative stress, resulting in 89 endothelial dysfunction—a critical precursor to atherosclerosis and an elevated risk of 90 cardiovascular events.³ Affecting about 9.1% of the global population, as the World 91 Health Organization reported in 2023, CKD is diagnosed and monitored by measuring 92 the estimated glomerular filtration rate (e GFR), utilizing the CKD-EPI equation. An 93 eGFR below 60 mL/min/1.73 m² signifies notable kidney impairment.^{4,5} Research by ⁹⁴Go et al. has demonstrated a clear, graded association between declining eGFR and 95 increased cardiovascular events. $6,7$ Additionally, studies focusing on older adults reveal 96 that the risk of CVDs increases from 15% for those with an eGFR of 90 mL/min/1.73 97 m² to 40% for individuals at 30 mL/min/1.73 m² over three years.⁸ The Framingham ⁹⁸Heart Study supports these findings, showing that individuals with mildly reduced 99 eGFR levels (60 to 79 mL/min per 1.73 m²) face a higher risk of CVDs than those with 100 higher eGFR. \degree These studies underscore the significance of eGFR as a robust 101 biomarker for assessing cardiovascular risk, highlighting its crucial role in clinical 102 practice.

103 Genome-wide association studies (GWAS) have identified hundreds of variants 104 contributing to the risk of eGFR and CVDs, some of which are shared risk loci. For 105 example, Graham and colleagues pinpointed 147 loci associated with eGFR, seven 106 demonstrating significant co-localization with cardiovascular traits, highlighting a 107 genetic link between eGFR and various CVD phenotypes.¹⁰ Genetic pleiotropy, where 108 a single genetic variant influences multiple traits, is prevalent in complex human 109 diseases, particularly in loci associated with CVDs. This pleiotropy can be vertical,

¹¹⁰where a variant's effect on one trait impacts another, or horizontal, where a variant 111 independently affects several traits. Mendelian randomization (MR) analyses utilizing 112 vertical pleiotropy have estimated causal relationships between eGFR and CVDs. For 113 example, Kelly et al. established a causal link between declining eGFR and increased 114 stroke risk, 11 while Geurts et al. identified a bidirectional causal relationship between 115 eGFR and atrial fibrillation (AF) .^{12,13} However, recent studies suggest that eGFR does 116 not significantly affect other CVDs, such as AF, coronary artery disease (CAD), stroke, 117 and heart failure (HF). These inconsistencies in MR results, possibly due to residual ¹¹⁸biases and unmeasured confounders, necessitate further investigation. Furthermore, the 119 study by Gong et al. highlights the role of horizontal pleiotropy in explaining the 120 common genetic architecture of human phenotypes, within the context of recent 121 advances in genomic statistical tools.¹⁴ Despite these advances, the extent of horizontal 122 pleiotropy between eGFR and CVDs still needs to be explored, and the common 123 genetic mechanisms must be fully elucidated. Therefore, there is a critical need for 124 systematic research to investigate the shared genetic architectures between eGFR and ¹²⁵CVDs, to identify shared polygenic risk variants, and to explore the involvement of 126 specific molecular biological pathways.

127 In this study, we conducted an extensive analysis leveraged the latest GWAS summary 128 statistics for European ancestry to explore the genetic associations between eGFR and 129 six major CVDs, including AF, CAD, Venous Thromboembolism (VTE), HF, ¹³⁰Peripheral Artery Disease (PAD), and Stroke. Firstly, the shared genetic basis is 131 determined by quantifying the overall and local genetic correlations and exploring the 132 overall genetic overlap. On this common genetic basis, in-depth research was 133 conducted on the potential genetic mechanisms underlying these traits. Regarding ¹³⁴horizontal pleiotropy, first, pleiotropy variation at the single nucleotide polymorphism ¹³⁵(SNP) level is detected, and then co-localization analysis is performed to locate 136 candidate causal variations accurately. Subsequently, position mapping and expression 137 quantitative trait loci (eQTL) mapping were used at the gene level to identify candidate ¹³⁸multi-effect genes. In addition, we conducted enrichment analysis on biological

- 139 pathways and elucidated the biological functions of genes associated with multiple
- 140 effector sites. We also investigated the potential association between plasma protein
- 141 levels and disease susceptibility and evaluated its potential as a therapeutic target.
- ¹⁴²Finally, MR analysis was conducted at the level of vertical pleiotropy, using whole
- 143 genome SNP data to estimate bidirectional causal effects while considering
- ¹⁴⁴confounding factors and sample overlap.In conclusion, our comprehensive analysis of
- 145 pleiotropy revealed the intricate genetic interactions between eGFR and CVDs. This
- 146 work provides a promising path for a deeper understanding of their genetic associations,
- ¹⁴⁷laying a solid foundation for future studies and driving new insights and targets in
- 148 prevention, early diagnosis, and personalized treatment.

149

¹⁵⁰**Methods**

¹⁵¹**Study Design**

- 152 Figure 1 presents the workflow for this study.
-

¹⁵⁴**Data selection and quality control**

¹⁵⁵GWAS summary statistics for eGFR were sourced from the most extensive publicly 156 accessible meta-analysis to date, encompassing two primary datasets $(n = 1,004,040)$: (i) 157 from the CKDGen consortium and (ii) from the UK Biobank.¹⁵ Similarly, we selected ¹⁵⁸six major CVDs from large meta-analyses for greater statistical power and clinical 159 relevance. We extracted GWAS summary statistics for AF from a genome-wide ¹⁶⁰meta-analysis that included 60,620 cases and 970,216 controls of European ancestry 161 across six studies: The Nord-Trøndelag Health Study (HUNT), deCODE, the Michigan 162 Genomics Initiative (MGI), DiscovEHR, UK Biobank, and the AFGen Consortium.¹⁶ ¹⁶³GWAS summary statistics for CAD were from a meta-analysis encompassed 181,522 164 cases and 984,168 controls of European ancestry, amalgamating data from nine studies 165 not previously included along with data from the UK Biobank and 166 CARDIoGRAMplusC4D consortium.¹⁷ GWAS summary statistics for VTE were

167 obtained from a meta-analysis of seven cohorts, including the Copenhagen Hospital 168 Biobank Cardiovascular Disease Cohort (CHB-CVDC), Danish Blood Donor Study ¹⁶⁹(DBDS), Intermountain Healthcare, deCODE, UK Biobank, Million Veteran Program 170 (MVP), and FinnGen, totaling 81,190 cases and $1,419,671$ controls.¹⁸ GWAS summary 171 statistics for HF included data from 47,309 cases and 930,014 controls across 26 studies 172 from the Heart Failure Molecular Epidemiology for Therapeutic Targets (HERMES) 173 Consortium.¹⁹ GWAS summary statistics for PAD involved 12,086 cases and 499,548 174 controls from a genome-wide meta-analysis comprising 11 independent studies.²⁰ ¹⁷⁵GWAS summary statistics for Stroke were sourced from a meta-analysis by the ¹⁷⁶GIGASTROKE consortium, which included 73,652 patients and 1,234,808 control 177 individuals.²¹ All summary statistics are based on individuals of European ancestry due 178 to the limited availability of well-powered GWAS for other ancestries. Further details 179 about the traits are available in eTable 1 in Supplement 1.

181 Before further analysis, we implemented rigorous quality control measures on these ¹⁸²GWAS summary statistics by aligning them with the 1000 Genomes Project Phase 3 ¹⁸³European population based on the hg19 genome build, removing SNPs lacking rsIDs or ¹⁸⁴with duplicate rsIDs, restricting the analysis to autosomal chromosomes, and retaining 185 only SNPs with a minor allele frequency (MAF) greater than 0.01. A total of 6,907,393 186 SNPs were included in the final analysis.

187

¹⁸⁸**Genetic correlation between eGFR and CVDs**

189 In order to investigate the possible shared genetic basis of eGFR and CVDs, we 190 estimated SNP-based heritability (h^2_{SNP}) and evaluated genome-wide genetic 191 correlation (r_e) by means of cross-trait linkage disequilibrium (LD) score regression 192 (LDSC) method.²² LDSC estimates the genetic contribution to complex diseases and 193 traits by quantifying the LD between each SNP and its neighbors. Initially, we 194 performed univariate LDSC to estimate h^2_{SNP} , which reflects the proportion of 195 phenotypic variation in a trait explained by shared genetic variants. LD scores were 196 calculated for each SNP using genotypes of common SNPs within a 10 Mb window

197 sourced from the 1000 Genomes Project Phase 3 European population. SNPs in the ¹⁹⁸major histocompatibility complex (MHC) region (chromosome 6: 25-35 Mb) were 199 excluded due to their intricate LD structure. We then conducted bivariate LDSC to 200 assess the r_g between eGFR and CVDs, using regression of LD scores against the 201 product of z statistics from the respective diseases and traits. The r_g ranges from -1, 202 representing a complete negative correlation, to $+1$, representing a complete positive 203 correlation, with values closer to these extremes indicating stronger correlations. The 204 intercept from LDSC may indicate a possible sample overlap among the GWAS data 205 sets; however, it is possible to estimate the r_g in an unbiased manner, even with 206 overlapping samples. After evaluating all pairwise r_g , we applied a Bonferroni correction for multiple comparisons, setting the significance threshold at $P < 8.33 \times 10^{-3}$ 208 $(0.05 / 6)$.

209 209

210 In order to evaluate the biological basis of the shared genetic predisposition to eGFR 211 and CVDs, we performed stratified LDSC applied to specifically expressed genes ²¹²(LDSC-SEG) to identify possible enrichment of related tissue and cell types. This ²¹³method integrates multi-tissue gene expression data from sources like the ²¹⁴Genotype-Tissue Expression (GTEx) and Franke Lab, as well as multi-tissue chromatin 215 information from the Roadmap Epigenomics and ENCODE datasets. The GTEx 216 project provided statistics representing key tissue types and their specific expression ²¹⁷across 49 tissues using baseline models and complete genomes. Additionally, we 218 incorporated tissue-specific histone marker annotations from the Roadmap ²¹⁹Epigenomics project. This included narrow peaks for DNase Hypersensitivity, ²²⁰H3K27ac, H3K4me1, H3K4me3, H3K9ac, and H3K36me3 chromatid. For identified 221 relevant tissues or cell types, we used the false discovery rate (FDR) method to correct 222 for each dataset, with a significance threshold of $FDR < 0.05$.

223

²²⁴**Genetic overlap between eGFR and CVDs**

²²⁵LDSC primarily measures the average genetic correlation of effect sizes for all SNPs 226 across the genome. This approach can potentially obscure the shared genetic

227 architectures involving a mixture of concordant and discordant effect directions and ²²⁸may fail to capture specific overlapping loci and relevant genes. To address this 229 limitation and quantify the polygenic overlap between eGFR and CVDs, we employed 230 the causal mixture modeling approach $(MiXeR)^{23}$ Firstly, univariate MiXeR analyses 231 were performed to estimate polygenicity (i.e., the count of variants explaining 90% of 232 h^2_{SNP}) and discoverability (the proportion of phenotypic variance attributable to causal 233 variant effect sizes).²³ We used data from the 1000 Genomes Project Phase 3 European 234 population for our analyses and excluded SNPs within the structurally complex MHC 235 region (CHR 6: 26-35 Mb). Subsequently, bivariate MiXeR analyses were conducted to 236 ascertain the total count of trait-specific and shared causal SNPs visually represented in 237 Venn diagrams. This delineation covers four components: unique causal variants for 238 trait 1, unique for trait 2, shared causal variants, and shared non-causal variants. MiXeR 239 calculates Dice coefficient scores (ranging from 0 to 1) to gauge polygenic overlap and 240 estimates the proportion of SNPs with concordant effects within the shared genetic 241 component. Additionally, MiXeR computes the r_g and the correlation of effect sizes 242 within the shared genetic component $(r_g s)$. To evaluate model fit, indicative of MiXeR's 243 predictive accuracy against actual GWAS data, we constructed conditional 244 quantile-quantile $(Q-Q)$ plots, used the Akaike Information Criterion (AIC), and 245 generated log-likelihood plots. A model-based Q-Q plot that closely aligns with the 246 actual Q-Q plot indicates strong predictive capability. A positive AIC value suggests 247 the model adequately distinguishes itself from comparative models, indicating a 248 reliable fit. Conversely, a negative AIC implies that the MiXeR model does not ²⁴⁹significantly differentiate from scenarios of maximum or minimum genetic overlap, 250 rendering the genetic overlap estimate potentially unreliable.

251 251

²⁵²**Local genetic correlation between eGFR and CVDs**

²⁵³To estimate local genetic correlations (local-*rgs*) between eGFR and CVDs within 254 specific genomic regions and identify loci with mixed effect directions, we utilized the 255 Local Analysis of $[co]$ Variant Annotation $(LAVA)$ ²⁴ LAVA captures detailed patterns 256 of shared genetic loci across individuals, revealing mixed effect directions obscured by

257 genome-wide r_g estimates due to opposing effects across genomic regions. Unlike the 258 genome-wide correlation analysis using LDSC, which considers the entire genome, 259 LAVA divides the genome into 2,495 local LD blocks and estimates r_g within each 260 block. Differing from MiXeR's method of estimating the proportion of shared 'causal' 261 variants with concordant effects, LAVA identifies mixed effect directions by capturing 262 significantly correlated genetic loci. Our study began with a univariate LAVA analysis 263 to estimate local heritability for each phenotype, considering loci with p -values \lt 1×10^{-4} as significant genetic signals. This approach identified 425 loci for subsequent 265 bivariate tests to estimate pairwise bivariate local- r_{ϱ} s across the genome. We adjusted 266 the p-values for local- r_{g} based on the number of bivariate tests, setting a 267 Bonferroni-corrected significance threshold at $P < 1.18 \times 10^{-4}$ (0.05/425).

268

²⁶⁹Additionally, we employed Hypothesis Prioritisation for multi-trait Colocalization ²⁷⁰(HyPrColoc) on genomic regions with shared risk loci across multiple phenotypes to 271 elucidate potential biological mechanisms linking traits. HyPrColoc, a Bayesian ²⁷²approach, identifies clusters of co-localization and candidate cause variants in the same 273 genomic locus. It estimates the posterior probability (PP) of colocalization of multiple 274 traits within a single causal variant, considering $PP > 0.7$ as significant evidence of 275 colocalization. This method enhances our understanding of how genetic variants 276 contribute to multiple traits, offering insights into complex trait interactions.

²⁷⁸**Mendelian randomization analysis between eGFR and CVDs**

²⁷⁹The genetic correlation and overlap analysis explored the shared genetic foundation 280 between eGFR and CVDs; however, whether their relationship is mediated by vertical 281 or horizontal pleiotropy remains unclear. Latent Heritable Confounder Mendelian 282 Randomization (LHC-MR)²⁵ provides valuable insights into the causal relationship 283 between eGFR and CVDs by utilizing vertical pleiotropy. This approach makes full use 284 of all genome-wide variations, improves statistical capacity, and corrects for sample 285 overlap, rather than just significant loci throughout the genome. Critically, LHC-MR is 286 able to distinguish between SNPs according to their co-association with a set of traits,

287 and to differentiate heritable confounding that results in r_g . This capability allows ²⁸⁸LHC-MR to provide concurrent unbiased estimates of bidirectional causal and 289 confounder effects. The LHC-MR framework accommodates multiple pathways 290 through which SNPs can affect the traits, including allowing for null effects, thereby 291 enabling precise causal effect estimations. Causal estimates from LHC-MR are 292 presented as odds ratios (ORs) with corresponding 95% confidence intervals (CIs). 293 Causality is considered unidirectional if P is lower than the Bonferroni-corrected threshold $(0.05 / 6 / 2 = 4.17 \times 10^{-3})$ and the *P*-value of the effect in the opposite direction is greater than 0.05. Bidirectional causality is considered if $P < 4.17 \times 10^{-3}$ in 296 both directions. Additionally, we employed several methods as sensitivity analyses to 297 validate the results, including the inverse variance weighted (IVW) method, the 298 weighted median, MR-Egger, simple mode, and weighted mode. These analyses help 299 confirm the robustness of the causal inferences drawn from our study.

300

³⁰¹**SNP-level analysis**

³⁰²**Identification of pleiotropic loci between eGFR and CVDs**

³⁰³In order to explore the effect of horizontal pleiotropy between eGFR and CVDs, we ³⁰⁴used Pleiotropic Analysis under the Composite Null Hypothesis (PLACO) to clarify the shared genetic mechanisms underlying these conditions.²⁶ PLACO identifies

306 pleiotropic loci between two traits by testing the compound null hypothesis that a locus

307 is related to either none or only one of them. This hypothesis is further subdivided into

308 specific sub-scenarios: (1) M00, indicating no association with any trait; (2) M10 and

³⁰⁹M01, each indicating an association with only one of the traits; and (3) M11,

310 representing a pleiotropic association with both traits. This method calculates the

311 PLACO statistics by multiplying the Z-scores of the two traits $(Z_{\text{tail}} \times Z_{\text{train2}})$ while

312 excluding SNPs with squared Z-values above 100 to mitigate spurious signals of

313 pleiotropy. SNPs are considered to exhibit significant genome-wide pleiotropy if their

314 *P_{PLACO}* is less than 5×10^{-8} .

315

³¹⁶**Genomic loci definition and functional analysis**

317 To identify pleiotropic SNPs associated with eGFR and CVDs, we utilized the 318 Functional Mapping and Annotation of Genome-Wide Association Studies (FUMA) 319 platform. FUMA integrates data from a variety of biological databases to improve 320 functional annotation, gene prioritization, and interactive visualization of GWAS 321 outcomes.²⁷ We calculated LD scores using the 1000 Genomes Phase III European 322 population as a reference. Firstly, independently significant SNPs achieving genome-wide significance ($P < 5.0 \times 10^{-8}$ and $r^2 < 0.6$) were identified. Lead SNPs 324 were then determined based on their independence $(r^2 < 0.1)$. Genomic risk sites were 325 delineated by merging lead SNPs within 500 kb of each other, allowing these sites to 326 contain multiple lead SNPs. The top lead SNP at each site, defined by the lowest P 327 value, was selected. Additionally, the directional impact of these sites was assessed by 328 comparing Z-scores between eGFR and CVD, providing insights into their potential 329 roles in these conditions. A GWAS site was considered novel if none of its lead, 330 independent, or candidate SNPs overlapped with SNPs previously reported in GWAS ³³¹meta-analyses. Using LocusZoom, we created a regional association plot with gene 332 tracks, allowing us to examine the details of the relationship between each locus. To 333 predict the functional outcomes of Top SNPs, we matched SNPs to databases 334 containing established functional annotations, including the Annotate Variation ³³⁵(ANNOVAR) category, Combined Annotation-Dependent Depletion (CADD) score, 336 RegulomeDB (RDB) score, and chromatin state. $28-30$ The CADD score is used to 337 predict the deleteriousness of SNP effects, incorporating 63 functional annotations. A 338 threshold of 12.37 is generally recognized as indicative of deleterious variants, and thus, 339 we filtered SNPs with a CADD score greater than 12.37 for location mapping. In order 340 to prioritize eQTL genes and explore their potential regulatory role, we used ³⁴¹RegulomeDB, which provides functional interpretation of SNPs based on curated 342 references. The RegulomeDB scoring system, ranging from 1a (most regulatory 343 potential) to 7 (least), helps evaluate the regulatory likelihood of SNPs. Additionally, 344 chromatin states were used to delineate the regulatory landscape of genomic regions, 345 with 15 classes of states predicted using 5 chromatin markers across 127 epigenomes 346 via the ChromHMM tool.³¹ Two methods were employed to map SNPs to genes: (i)

347 positional mapping, which assigns SNPs to genes based on their physical proximity ³⁴⁸(within a 10kb window) to known protein-coding genes in the human reference 349 assembly, and (ii) eQTL mapping, which links SNPs to genes based on significant ³⁵⁰eQTL associations, where allelic variations in an SNP correlate with variations in gene 351 expression levels, as identified using the GTEx database. This approach improves our ³⁵²understanding of the genetic structure by linking SNPs to potential functional 353 outcomes.

³⁵⁵**Colocalization analysis**

³⁵⁶For FUMA-annotated pleiotropic loci, we performed a Bayesian colocalization 357 analysis to identify potential common causal variations between trait pairs. COLOC ³⁵⁸employs a Bayesian framework to calculate the PP of five distinct hypotheses 359 concerning shared causal variation within a genomic region.³² These hypotheses assess ³⁶⁰whether one or both traits share causal variations at a specific locus. Specifically, the 361 hypotheses are as follows: i) PPH0: Neither trait has causal variation at the locus; ii) ³⁶²PPH1: Only the first trait has causal variation at the locus; iii) PPH2: Only the second 363 trait has causal variation at the locus; iv) PPH3: Each trait has a different causal 364 variation within the locus; v) PPH4: Both traits share a causal variation within the 165 locus.³³ The SNP exhibiting the highest PPH4 within the locus is identified as the 366 candidate causal variant. Loci are considered colocalized if the PPH4 exceeds 0.7, ³⁶⁷indicating a strong likelihood that the locus harbors shared causal variations for the 368 traits under study.

- 369
- 370

³⁷¹**Gene-level analysis using MAGMA, eMAGMA and TWAS**

To identify candidate pleiotropic genes further, we conducted Multi-marker Analysis of GenoMic Annotation (MAGMA) based on results from PLACO and individual GWAS. MAGMA uses the SNP average model within the multi-regression framework to derive *P* values, and to estimate the association of the gene, and to adjust for factors such as the size of the gene, the number of SNP for each gene, and the LD between markers.³⁴

³⁷⁷Our analysis referenced the 1000 Genomes Project Phase 3 European population and 378 used the Genome Reference Consortium Human Build 37 (hg19) for SNP locations and 379 gene annotations. We analyzed 17,636 protein-coding genes on the MAGMA software ³⁸⁰website, focusing on genes containing at least ten SNPs to ensure computational 381 stability. Gene based testing involves extending 10kb upstream and downstream of the ³⁸²gene transcription start and end sites. Because of their complicated LD patterns, we 383 ruled out MHC regions (chr6: 25 - 35 Mb). Strict Bonferroni correction was used for 384 adjustment for multiple trials, and in the MAGMA analysis based on the PLACO results, a significant threshold of $P < 4.23 \times 10^{-7}$ (0.05 / 17636 / 6) was established. 386

³⁸⁷The inherent limitations of MAGMA, which assigns SNPs based solely on proximity to ³⁸⁸genes without accounting for functional associations such as gene regulation, can 389 hinder its effectiveness in elucidating the underlying mechanisms of genetic variants. ³⁹⁰To overcome this and delve deeper into the functional implications of genetic variants 391 associated with eGFR and CVDs, we employed the EQTL-informed MAGMA 392 $\left(E\text{-}MAGMA\right)^{35}$ Operating within the same statistical framework as MAGMA, ³⁹³E-MAGMA uses a multi-principal component linear regression model to leverage 394 tissue-specific eQTL data from multiple sources, aiming to identify potential causal 395 genes for phenotypic traits. Our study utilized eQTL data from 47 tissues, enriched for 396 differentially expressed genes in tissues as provided by the Genotype-Tissue ³⁹⁷Expression Project version 8 (GTEx v8), and referenced the 1000 Genomes Project ³⁹⁸Phase 3 European population. To mitigate potential confounding effects from the broad 399 range of tissues, we focused on 11 specific tissues that were identified by LDSC-SEG ⁴⁰⁰analysis, including arterial, adipose, cardiac, whole blood, liver, EBV-transformed ⁴⁰¹lymphocytes, and kidney tissues. We excluded kidney tissue from our analysis due to 402 the absence of reference in E-MAGMA. We applied Bonferroni-adjusted p -value ⁴⁰³thresholds to accommodate multiple testing, calculated based on the number of genes ⁴⁰⁴analyzed in E-MAGMA and the number of statistically significant trait pairs tested. For 405 example, the threshold for subcutaneous fat was defined as $P < 8.67 \times 10^{-7}$ (0.05 / 9,603) 406 $/ 6$).

Pathway-level analysis using MAGMA and Metascape

We conducted a MAGMA gene set analysis to elucidate the biological functions of 423 genes exhibiting pleiotropic effects on eGFR and CVDs. This analysis employs a 424 competitive gene set framework to assess whether specific gene sets are more strongly associated with a particular phenotype than the broader genomic background. Our approach integrates gene definitions and their respective signals using MAGMA's 427 gene-based multi-marker method. The analyzed gene set is derived from Gene Ontology (GO) and Reactome pathways, as listed in the Molecular Feature Database 429 (MSigDB v7.5). The significance threshold was set to $P < 0.05 / (7744 + 1654) / 6$, 430 adjusted for the number of GO and Reactome pathways, as well as the number of trait pairs analysed. To elucidate the biological processes and signaling pathways associated 432 with eGFR and CVDs, we conducted Metascape analysis on the overlapping genes identified by MAGMA and EMAGMA. Metascape provides comprehensive annotation 434 of gene and protein, enrichment analysis, and protein-protein interaction networks, 435 which can help to better understand the functions of genes.³⁷ We used Metascape to 436 perform GO annotation and Reactome enrichment analysis, which utilizes the

437 hypergeometric test to identify significant ontology terms. The GO resource offers a ⁴³⁸framework and concepts to describe gene product functions across all organisms, while 439 the Reactome knowledgebase details cellular processes, such as signaling, transport, ⁴⁴⁰DNA replication, and metabolism, as ordered networks of molecular transformations. 441 Pathways with a *p*-value \leq 0.01 were considered significant.

442

⁴⁴³**Proteome-wide Mendelian Randomization analysis using SMR**

⁴⁴⁴To investigate potential associations between plasma protein levels and disease 445 susceptibility, we employed Summary data-based Mendelian Randomization (SMR). ⁴⁴⁶This analysis integrated plasma protein quantitative trait locus (pQTL) summary 447 statistics from the UK Biobank Pharmaceutical Proteomics Project (UKB-PPP) with ⁴⁴⁸GWAS summary statistics for various diseases. The UKB-PPP data, derived from the 449 Olink proteomics platform, includes genetic associations for 2,940 plasma proteins 450 across a cohort of 34,557 Europeans. In this context, cis-pQTLs are defined as SNPs 451 located in the 1Mb window surrounding the transcription start site (TSS) of each 452 protein. For SMR analysis, we only took into account the cis-pQTLs related to plasma 453 protein levels at the genome-wide significance threshold ($P < 5 \times 10^{-8}$). SMR, a method 454 that utilizes summary-level data, assesses potential causal relationships between ⁴⁵⁵exposures (e.g., plasma protein levels) and outcomes (e.g., traits or diseases). In order 456 to distinguish between pleiotropy and linkage in the cis-p QTL region, we tested 457 multiple SNPs using the heterogeneity of instrument-dependent (HEIDI) method. 458 Results indicating pleiotropy (HEIDI test $P < 0.01$) were excluded from further analysis. ⁴⁵⁹In recognition of the limitations of single-SNP analyses, we also performed a 460 sensitivity analysis using a multi-SNP-SMR test, with a P value of < 0.05 being 461 significant. A Bonferroni correction was applied to the number of unique proteins to be 462 analyzed, and a significance threshold was set at $P < 3.65 \times 10^{-6}$ (0.05 / 1958 / 7). 463 Additionally, we performed COLOC analysis to determine if the same causal variation 464 is responsible for the association of protein levels with disease phenotype. The PP.H4 $>$ ⁴⁶⁵0.7 for shared causal variants indicates significant colocalization of GWAS and pQTL.

⁴⁶⁷**Result**

⁴⁶⁸**Genome-wide genetic correlation between eGFR and CVDs**

After implementing stringent quality control, we utilized LDSC to assess h^2_{SNP} and 470 genome-wide r_g between eGFR and CVDs. We used univariate LDSC to estimate h^2_{SNP} for eGFR and each CVD. The SNP heritability estimate was highest for eGFR $(h^2_{SNP} =$ 472 0.0708 , SE = 0.0036). Among these CVDs, heritability estimates ranged from 0.0060 473 for Stroke, the lowest ($SE = 0.0005$), to 0.0324 for CAD, the highest ($SE = 0.0019$) ⁴⁷⁴(Supplementary Fig. 1a and Supplementary Table 2a).We then conducted bivariate 475 LDSC analysis to explore the r_g between eGFR and CVDs. This revealed significant 476 negative r_g for two trait pairs: eGFR and Stroke (r_g = -0.0985, SE = 0.0309) and eGFR 477 and VTE $(r_g = -0.0783, SE = 0.0238)$, both surpassing the Bonferroni-corrected 478 significance threshold ($P < 8.33 \times 10^{-3}$) (Supplementary Fig. 1b and Supplementary 479 Table 2b). However, no significant r_g was found between eGFR and AF, CAD, HF, or 480 PAD.

481

⁴⁸²**Polygenic overlap and local genetic correlation between eGFR and CVDs**

483 Nevertheless, previously described r_g may underestimate the genetic overlap between 484 eGFR and CVDs. The fact that there is no significant r_g does not necessarily mean that 485 there is no common genetic component among these traits. Indeed, the r_g measure does 486 not distinguish between mixtures of concordant and discordant genetic effects and a 487 true absence of genetic overlap. To address this limitation and more comprehensively 488 elucidate the shared genetic underpinnings of complex polygenic features, we 489 employed advanced analytical tools, MiXeR and LAVA, specifically designed to ⁴⁹⁰provide more detailed insights into genetic architectures that traditional analyses might 491 obscure.

We conducted MiXeR analyses to quantify the polygenic genetic overlap between eGFR and CVDs, accounting for mixed effect directions. Initially, univariate MiXeR 495 analyses estimated that approximately 2,044 variants $(SD = 111)$ influence eGFR. Among the CVDs, HF had the highest polygenicity, with 2,286 'causal' variants

accounting for 90% of HF h^2_{SNP} (SD = 215), followed by CAD with 1,431 variants (SD 498 = 311), and stroke with 1,039 variants (SD = 120) (Supplementary Table 3a). 499 Subsequently, bivariate analyses revealed significant polygenic overlap between eGFR 500 and these CVDs, with Dice coefficients ranging from 0.024 to 0.457 (Fig. 2a, 501 Supplementary Fig. 2, Supplementary Table 3b). Notably, eGFR displayed a moderate 502 genetic overlap with diseases like CAD (Dice $= 0.457$), HF (Dice $= 0.39$), and stroke 503 (Dice $= 0.35$). Among these, the eGFR-HF pair possessed the highest number of shared ⁵⁰⁴'causal' variants (841, SD=151), accounting for substantial proportions of variants 505 affecting each condition (41.1% for eGFR and 36.8% for HF), suggesting highly 506 similar genetic architectures between these two traits. However, the genetic correlation 507 (4.78 \times 10⁻⁴, SD=9.83E-3) and the correlation coefficients of genetic risk (9.62 \times 10⁻⁴, 508 SD=0.024) between eGFR and HF were notably weak. This extensive genetic overlap, 509 coupled with weak r_g , highlights the existence of mixed effects, as demonstrated by the 510 proportion of shared 'causal' variants with consistent effects $(0.50, SD = 0.007)$. A 511 similar relationship was observed between eGFR-CAD and eGFR-Stroke, with the r_g 512 and $r_g s$ (r_g = -0.098; $r_g s$ = -0.269) of eGFR-Stroke consistent with their ⁵¹³LDSC-estimated significant negative genetic correlations. Compared to diseases with 514 lower polygenicity, such as AF, VTE, and PAD, eGFR is characterized as a highly 515 polygenic trait, leading to significant disparities in the number of shared and unique 516 causal' variants. For instance, the eGFR-VTE pair demonstrated mild genetic overlap 517 (Dice $= 0.177$) with 211 shared variants (SD $= 83$), accounting for 10.3% of eGFR's and 518 66.2% of VTE's heritability, and exhibited the highest genetic risk correlation (r_g = 519 -0.115 , SD = 0.007). Conversely, the eGFR-PAD pair had the fewest shared variants (28, 520 SD = 15), but the shared genetic components showed the strongest correlation ($r_{g}s=$ 521 0.567, SD $=0.351$), indicating that while many eGFR-associated variants do not 522 influence PAD, those that do have highly similar effects (Supplementary Fig. 2).

523

524 LAVA, which calculates local- r_g s, was employed to explore further the relationships 525 between eGFR and CVDs, revealing mixed effect directions. First, univariate analyses 526 were conducted to identify heritable regions, filtering out loci devoid of univariate

527 heritability (Supplementary Table 4), leading to 425 bivariate tests. While no 528 significant genome-wide r_g emerged between eGFR and diseases such as AF, CAD, HF, 529 or PAD, LAVA identified specific regions with significant local- r_{g} s ($P < 0.05$, Fig.2b 530 and Supplementary Table 5). This was particularly notable between eGFR and CAD, 531 where 27 positively and 28 negatively correlated regions were found, suggesting that 532 the overall non-significant genome-wide correlation could result from 533 counterbalancing local effects. Similarly, mixed effects were observed with other 534 diseases: eGFR and AF exhibited 17 positive and 18 negative regions, HF showed 5 535 positive and 4 negative regions, and PAD had an equal number of positive and negative 536 regions (4 each). Contrary to these, eGFR and VTE displayed more negatively 537 correlated regions $(12 \text{ positive} / 23 \text{ negative})$, aligning with the negative genome-wide 538 correlations estimated by LDSC. However, the findings for eGFR and Stroke, which 539 presented more positively than negatively correlated regions, did not consistently align 540 with the negative r_g estimated by LDSC, though 5 negatively correlated regions were 541 still identified. After applying the Bonferroni correction, 36 genetic regions showed 542 significant local-r_gs. Notably, three genetic regions were linked to multiple trait pairs: ⁵⁴³LD block 96 on chromosome 1 was associated with both eGFR-CAD and eGFR-VTE; ⁵⁴⁴LD blocks 673 on chromosome 4 and 1057 on chromosome 6 exhibited correlations 545 between eGFR-AF and eGFR-CAD. Further analysis using HyPrColoc identified 546 shared causal variants, with SNP rs12740374 in LD block 96 showing strong 547 co-localization evidence of influencing eGFR-VTE and CAD with a PP greater than 548 0.7.

550 In summary, we systematically quantified the genetic overlap between eGFR and six 551 major CVDs using MiexR and LAVA, going beyond simple genome-wide r_g . These ⁵⁵²analyses highlighted significant shared genetic bases between eGFR and the CVDs, ⁵⁵³which were not apparent from traditional genome-wide studies alone. Building on these 554 findings, we performed further pleiotropy analysis to delve deeper into the molecular 555 mechanisms underlying these trait pairs.

556

⁵⁵⁷**Causal effects identified between eGFR and CVDs**

558 Based on the above-mentioned common genetic basis between eGFR and CVDs, we 559 implemented multiple pleiotropy methods to reveal the potential mechanisms of 560 vertical or horizontal pleiotropy. Among them, in terms of vertical pleiotropy, we used ⁵⁶¹LHC-MR technology to study causal relationships while controlling bias and 562 confounding factors. Our analysis found that AF had a significant reverse causal effect 563 on eGFR (OR: 0.806; 95% CI = 0.720 to 0.903), which suggests that the presence of AF ⁵⁶⁴may reduce eGFR. In addition, we observed another pair of significant negative causal 565 relationships, indicating that an increase in eGFR would reduce the risk of VTE (OR $=$ 566 0.931; 95% CI = 0.899 to 0.964) (Fig. 3, Supplementary Table 6a). These findings were 567 confirmed by the results of the IVW method. In summary, our MR study provides 568 strong evidence for the causal relationship between AF and eGFR and between eGFR 569 and VTE (Supplementary Fig. 5, Supplementary Table 6b). However, it must be 570 recognized that vertical pleiotropy alone cannot fully explain the common genetic basis 571 between eGFR and CVDs.

572 572

⁵⁷³**Pleiotropic genomic loci identified between eGFR and CVDs**

574 Given the extensive genome-wide genetic overlap, we further tested pleiotropic SNPs 575 between eGFR and CVDs by PLACO, and a total of 20,073 SNPs ($P < 5 \times 10^{-8}$) were 576 identified as significant pleiotropic variants. FUMA aggregated these SNPs into 508 577 loci, involving 226 unique chromosomal regions, of which 32 loci appeared in over 50% 578 of trait pairs (Fig. 4, Supplementary Fig 6, Supplementary Table 7). Notably, loci such 579 as 6q25.3 (SLC22A1), 8p23.1 (BLK), 9q34.2 (ABO), and 6p21.1 (*CRIP3*) showed 580 overlap across all six trait pairs, while $12q24.12$ (*ALDH2*) appeared in five. These 581 broad pleiotropic effects are exemplified by the common variants at $6p21.1$, which are 582 associated with both polycystic kidney disease and stroke, and by $12q24.12$, a locus 583 significant for CAD and stroke. Interestingly, 24 pleiotropic loci had not been reported 584 in previous eGFR and CVD studies, which reported 81 and 364 loci, respectively. 585 Targeted analysis within the 508 pleiotropic loci revealed that 139 top SNPs (27.4%) 586 indicated an increased risk for these traits, while 118 (23.2%) indicated a reduced risk.

587 The remaining 251 top SNPs (49.4%) showed discordant associations, highlighting 588 potential contrasting biological mechanisms. Functional annotation using FUMA 589 identified that 330 SNPs (65.0%) were intronic variants, 127 (25.0%) were intergenic, 590 and 21 (4.1%) were exonic, including 14 mRNA and 7 non-coding RNA exon variants. 591 Moreover, 40 SNPs in these risk loci, including rs34312154 with the highest CADD 592 score of 31, may be potentially harmful, affecting genes like *HOXB1* to *HOXB8*. ⁵⁹³Additionally, 58 SNPs identified by RegulomeDB as potentially affecting transcription 594 factor binding underscore the regulatory significance of these findings, with rs4918003 595 showing the most potent evidence of regulatory potential (RDB: 1b). 597 Further analysis of co-localization at 508 identified loci revealed that 74 loci (14.6%)

598 exhibit high PP (PPH4 > 0.7), indicating strong evidence of shared genetic signals (Fig. ⁵⁹⁹4, Supplementary Fig. 7, Supplementary Table 7). Of these, 71 top SNPs were 600 identified as candidate common pathogenic variants. Notably, the 1p13.3 locus showed 601 significant pleiotropy, influencing the trait pairs of eGFR-CAD, eGFR-VTE, and ⁶⁰²eGFR-HF, with PP.H4 values ranging from 0.956 to 0.998. Subsequent HyPrColoc ⁶⁰³analysis identified rs660240 in the CELSR2 gene at this locus as exhibiting strong ⁶⁰⁴co-localization for both eGFR and HF and eGFR and VTE, with PP exceeding 0.7.

605

⁶⁰⁶**Identification of pleiotropic genes between eGFR and CVDs**

We used MAGMA analysis to convert the SNP level signals of identified eGFR-CVDs into gene level signals, focusing on potential pleiotropy within or overlapping 508 609 pleiotropic loci. This analysis identified 802 significant pleiotropic genes, with 579 being unique. Notably, 379 genes were implicated in more than one trait pair, providing 611 robust statistical evidence for shared genetic inheritance across diverse traits (Fig. 5, 612 Supplementary Table 11). Specific genes such as *ATXN2* (located at 12q24.12) significantly impacted five trait pairs. Additionally, genes including *ABO* (9q34.2), *BRAP* (12q24.12), *SH2B3* (12q24.12), *L3MBTL3* (6q23.1), *MMP24* (19q13.32), *MRPS21* (1q21.2), and *PRPF3* (1q21.2) were significant across four trait pairs,

616 underscoring their pivotal roles in these genetic networks. Remarkably, the $12q24.12$ 617 locus, home to *ATXN2*, *BRAP*, and *SH2B3*, is critical in assessing genetic risks for 618 hypertension³⁸ and CKD, with $ATXN2$ linked to myocardial infarction, renal function, 619 and hypertension.³⁹ Among the genes identified, 118 were not previously explored in 620 eGFR studies, and 410 were new to CVD research, highlighting significant novel 621 findings. Positional mapping in FUMA confirmed 97.88% of these risk genes identified ⁶²²by MAGMA, further solidifying the evidence for a shared genetic framework across 623 these trait pairs (Supplementary Table 9).

624

⁶²⁵We employed the LDSC-SEG method to perform tissue-specific genetic analysis,

626 identifying distinct tissue associations for each trait. The analysis revealed significant

627 gene expression enrichment for eGFR in the renal cortex and liver tissues. Similarly,

⁶²⁸AF showed considerable enrichment in the atrial appendage and cardiac left ventricular

629 tissues, while CAD was significantly enriched in the aorta, coronary artery, and tibial

630 artery tissues, with all exceeding an FDR threshold of 0.05. Subsequent LDSC-SEG

631 chromatin analysis corroborated these findings, enhancing the resolution by detecting

632 significant tissue chromatin signals associated with eGFR, AF, and CAD traits

⁶³³(Supplementary Fig. 3, Supplementary Table 14).

634 634

We conducted E-MAGMA analysis on ten related tissues using tissue-specific eQTL information, which identified 1,276 pleiotropic genes that remained significant after Bonferroni correction, showing strong enrichment in at least one of the analyzed tissues (Supplementary Table 15). Particularly noteworthy, 26 genes were prevalent in over 50% of trait pairs, with *KAT5* and *PROCR* appearing in five trait pairs each and *BLK* and *SLC22A1* in four. *KAT5*, or lysine acetyltransferase 5, serves a dual role; it regulates the 641 level of acetylation of target proteins, affecting the expression of inflammation related genes and the intensity of inflammatory responses. This regulatory function is crucial, as abnormal expression or dysfunction of *KAT5* can elevate cardiovascular disease risks 644 by affecting the inflammatory pathway.⁴⁰ Additionally, *KAT5* acts as a DNA repair 645 factor, vital for preventing ischemic acute kidney injury (AKI), primarily by regulating

646 glomerular filtration.⁴¹ Therefore, the normal function and activity of *KAT5* are critical 647 in preventing or alleviating AKI and indirectly maintaining or enhancing eGFR levels. ⁶⁴⁸We also performed the TWAS to assess the tissue specificity of pleiotropic genes for 649 each trait, leading to the discovery of 354 new genes associated with eGFR and 142 650 new genes related to various CVDs (Supplementary Table 16). Furthering our 651 investigation, we utilized FUMA for eQTL mapping, identifing 2,049 genes, of which ⁶⁵²71.40% were confirmed by our analysis to be associated with the traits under study ⁶⁵³(Supplementary Table 9).

654

⁶⁵⁵MAGMA and E-MAGMA analyses have jointly identified 424 pleiotropic genes, ⁶⁵⁶including 314 unique ones, shedding light on the common mechanisms underlying 657 various trait pairs (Supplementary Table 11). Notably, 76 of these genes recur across ⁶⁵⁸multiple trait pairs, with genes such as *MMP24*, *L3MBTL3*, and *ABO* being prominent ⁶⁵⁹in half or more of the analyzed traits. Specific genes like *ABO* (9q34.13), *PROCR* ⁶⁶⁰(20q11.22), *BLK* (8p23.1), *ALDH2* (12q21.31), and *SLC22A1* (6q25.3) each featured in 661 three different trait pairs, highlighting their significant roles in multiple pathologies. 662 For instance, *L3MBTL3* has been implicated in renal dysfunction and cardiovascular ⁶⁶³pathogenesis, illustrating the interconnectedness of renal and cardiovascular systems. ⁶⁶⁴*MMP24*'s dysregulated expression, associated with renal tubular atrophy and diabetic 665 nephropathy (DN), may contribute to structural and functional kidney impairments that ⁶⁶⁶exacerbate cardiovascular risk. In addition, the *ABO* gene, which is associated with 667 changes in von Willebrand factor (VWF) plasma levels, plays a key role in regulating 668 platelet function and atherosclerosis, thus affecting the severity of CAD. While the 669 precise mechanisms connecting ABO genes to eGFR remain elusive, their association ⁶⁷⁰with conditions like type 2 diabetes (T2D) and hypertension, which are main risk 671 factors for CKD, likely impacts eGFR. 42

672

⁶⁷³**Shared biological mechanisms between eGFR and CVDs**

⁶⁷⁴We employed the MAGMA algorithm to assess pathway enrichment among the

675 identified genes, setting a stringent Bonferroni-corrected threshold $(P < 8.87 \times 10^{-7})$. 676 This analysis revealed 78 significantly enriched pathways, comprising 73 Gene ⁶⁷⁷Ontology Biological Process (GO BP) terms and 5 Reactome gene set pathways, ⁶⁷⁸indicative of key biological processes (Supplementary Table 17a). Notably, pathways ⁶⁷⁹such as the positive regulation of macromolecule biosynthetic processes, transcription 680 by RNA polymerase II, and RNA metabolic processes were enriched in half or more of 681 the trait pairs, highlighting their crucial roles in the regulation of core biological 682 processes that contribute to the development of the studied traits.

683

⁶⁸⁴Further analysis of pathway enrichment for overlapping genes, identified in multiple 685 trait pairs from MAGMA and E-MAGMA analyses, was conducted using the ⁶⁸⁶Metascape website (Supplementary Table 17b). This analysis pinpointed 16 ⁶⁸⁷significantly enriched pathways predominantly involved in regulating biosynthetic and ⁶⁸⁸metabolic processes, lipid metabolism, and receptor signal transduction. The pathways 689 related to glutathione breakdown and stem cell maintenance were critical and had 690 profound implications for eGFR and CVDs. The antioxidant and anti-inflammatory 691 properties of glutathione are essential for cardiovascular protection. However, its ⁶⁹²degradation may elevate the risk of CVDs through mechanisms linked to renal ⁶⁹³insufficiency. Moreover, the protective roles of endothelial progenitor cells (EPC) and 694 stem cell factor (SCF) within the kidney are critical for maintaining eGFR and CVDs 695 health, implying that diminished activity in these pathways could adversely affect renal 696 and cardiovascular systems.

⁶⁹⁸**Proteome-wide Mendelian Randomization analysis for eGFR and CVDs**

We conducted a SMR analysis utilizing GWAS summary data for eGFR, six major CVDs, and plasma protein pQTLs. This analysis identified 78 risk proteins, 32 linked 701 to eGFR and 46 to CVDs, validated through HEIDI evaluation $(P > 0.01)$, multiple 702 SNP-SMR sensitivity analysis ($P < 0.05$), and Bonferroni corrections ($P_{SMR} < 0.05$ / (1958×7)). Subsequently, we investigated potential pleiotropic effects within specific eGFR-CVD pairs, identifying three signature pairs that contain pleiotropic proteins

⁷⁰⁵(Supplementary Table 18). Notably, CELSR2 was common between eGFR-CAD and 706 eGFR-VTE, while FGF5 linked eGFR-AF and eGFR-CAD. Additionally, a ⁷⁰⁷colocalization analysis of these 78 proteins sought to identify common pathogenic 708 variants associated with specific eGFR or CVDs signatures. This analysis showed ⁷⁰⁹strong evidence of colocalization for 49 proteins (41 unique), with 17 proteins 710 associated with eGFR and 32 with CVDs. Proteins such as CELSR2 and FGF5, ⁷¹¹emphasized in the SMR analysis, displayed strong evidence of colocalization across 712 three identified signature pairs, underscoring a shared pathogenic pathway across these 713 conditions.

714

⁷¹⁵**Discussion**

716 In this study, a comprehensive genome-wide pleiotropy analysis was carried out to 717 investigate the genetic correlation and overlap between eGFR and CVDs, uncovering a 718 complex shared genetic foundation. Our detailed investigations identified key 719 pleiotropic loci and genes, including *L3MBTL3*, *MMP24*, and *ABO*, and illuminated 720 crucial biological pathways such as stem cell population maintenance and glutathione 721 metabolism. Additionally, using MR analysis, we indicated a causal relationship 722 between eGFR and VTE, as well as between AF and eGFR. Collectively, the results 723 provide a better understanding of the shared genetic etiology and biological ⁷²⁴mechanisms that underlie the relationship between eGFR and CVDs, opening new 725 avenues for targeted therapeutic strategies and further research.

726 726

⁷²⁷Our analysis probed the shared genetic architectures of eGFR and six major CVDs 728 using complementary genetic tools—LDSC, MiXeR, and LAVA—to reveal extensive 729 shared genetic bases across all trait pairs. LDSC highlighted significant negative global ⁷³⁰*rg* between eGFR and VTE and Stroke, contrasting with previous studies that reported 731 no significant associations. This underscores the advantage of our approach and the 732 benefits of a larger sample size. Despite the absence of significant global correlations 733 for certain traits, MiXeR identified substantial overlap for CAD, HF, and AF with ⁷³⁴eGFR, indicating mixed effect directions even when global correlations are not evident.

⁷³⁵LAVA provided further insights into local-*rgs*, revealing mixed effect directions not 736 apparent from genome-wide estimates, such as those observed between eGFR and ⁷³⁷CAD, which exhibited both positively and negatively correlated loci. This suggests a ⁷³⁸more nuanced genetic relationship than previously recognized. Moreover, employing 739 bivariate MiXeR revealed extensive genetic overlap between eGFR and CAD, 740 supported by LAVA's local- $r_{\rm g}$ s, highlighting concordant and discordant effect ⁷⁴¹directions. Our comprehensive analysis confirms the shared genetic foundations 742 between eGFR and various CVDs, indicating multiple common genetic variants 743 influencing critical biological pathways.

744

745 Our findings elucidate the shared genetic bases between eGFR and CVDs, attributable 746 to both horizontal pleiotropy and direct causal mechanisms (vertical pleiotropy). Our ⁷⁴⁷MR analysis effectively separated potential causal effects from other genetic influences. 748 Notably, the LHC-MR results identified a reverse causal relationship of eGFR on VTE, 749 a finding supported by Yuan et al.⁴³ This causal relationship is likely driven by impaired ⁷⁵⁰kidney function, which increases coagulation factors and decreases endogenous 751 anticoagulants, collectively promoting thrombus formation. Additionally, our analysis 752 indicates a potential causal influence of AF on eGFR, aligning with previous studies 753 that suggest AF can lead to renal impairments via mechanisms such as 754 thromboembolism and reduced renal microvascular blood flow.^{12,44} However, our 755 analysis did not establish causal relationships for other trait pairs, suggesting that while ⁷⁵⁶genetic overlaps between eGFR and CVDs are partially driven by causality, the 757 complexity of these relationships varies across different conditions.

Our cross-trait meta-analysis has identified many genome-wide significant pleiotropic 760 loci associated with eGFR and CVDs. Notably, loci such as 8p23.1 (*BLK*) and 6q25.3 (*SLC22A1*) demonstrated significance across six trait pairs, while others like 12q24.12 (*ALDH2*) and 20q11.22 (*PROCR*) were significant in over 50% of the trait pairs. 763 Specifically, the BLK gene at 8p23.1 enhances insulin synthesis and secretion, linking it to CKD symptoms and complications in nephropathy and diabetes by increasing the

765 production of pro-inflammatory cytokines. BLK is also identified as a susceptibility 766 gene for Kawasaki disease, 45 a systemic vasculitis that can impact coronary arteries and 767 increase CVDs risks.⁴⁶ Furthermore, the locus *SLC22A1* at 6q25.3 is associated with ⁷⁶⁸DN, a severe complication of diabetes characterized by persistent albuminuria, 769 declining eGFR, and elevated arterial blood pressure, which elevates the risk for CVDs 770 and cerebrovascular diseases.⁴⁷ The role of this locus in hypertension underscores its 771 potential as a mediator of underlying disease risks. The consistency of effect alleles in 772 nearly half of the significant SNPs for both eGFR and CVD supports a positive 773 association between these conditions and provides insights into their complex r_g .

775 Our analysis has identified several key pleiotropic genes in over 50% of the trait pairs, 776 including *L3MBTL3* (6q23.1), *MMP24* (20q11.22), and *ABO* (9q34.2). For example, ⁷⁷⁷*L3MBTL3* significantly influences the risk of coronary heart disease (CHD) by ⁷⁷⁸modulating adipogenesis, the process of fat cell differentiation. Dysfunctional adipose 779 tissue can lead to ectopic fat accumulation, which promotes insulin resistance and other ⁷⁸⁰metabolic disorders, escalating the risk for obesity-related CHD. These metabolic 781 disturbances further amplify the risk of ischemic stroke by intensifying common risk 782 factors (such as hypertension and diabetes). Although *L3MBTL3*'s expression in the ⁷⁸³kidney is documented, the specific mechanisms by which it affects renal function and 784 structure remain to be fully explored. Matrix metalloproteinase-24 (*MMP24*) plays a 785 key role in extracellular matrix degradation, and is linked with renal tubular atrophy 786 and the severity of alcohol-induced renal injury and fibrosis. Dysregulated *MMP24* 787 expression detrimentally impacts both renal and cardiovascular health. In DN, *MMP24* 788 is implicated in abnormal extracellular matrix accumulation, leading to significant 789 damage to the glomeruli and renal tubules and indirectly impacting $eGFR⁴⁸$ Given the 790 close association of DN with T2D, a prominent risk factor for CVDs, *MMP24*'s role in 791 DN could indirectly heighten the risk of CVDs.⁴⁹ The *ABO* gene, vital for determining ⁷⁹²blood group phenotypes, also affects crucial hemostatic factors such as VWF and factor 793 VIII (FVIII), which are essential for platelet adhesion at injury sites. Individuals with 794 non-O blood types generally exhibit higher VWF levels and are more susceptible to

795 VTE.⁵⁰ In addition, researchers have discovered a new connection between *ABO* and 796 primary glomerulonephritis, especially IgA nephropathy, where certain blood groups 797 are linked to an increased risk of renal function decline.⁵¹ These findings highlight the 798 complex interaction of genetics with the pathophysiology of renal and CVDs, which 799 provides a strong basis for further study of the mechanisms and risks associated with 800 genetic diseases.

801

802 Our study also examines the role of shared genetic determinants in two critical ⁸⁰³biological pathways, including stem cell population maintenance and glutathione 804 catabolism, and their implications for kidney function and cardiovascular health. In the stem cell maintenance pathway, $MMP24^{52}$, $PSRC1^{53}$, and $CHMP1A^{54}$ play pivotal roles ⁸⁰⁶by regulating the stem cell cycle, ensuring cellular quiescence, and preventing 807 premature differentiation, respectively. These molecular actions are crucial for 808 promoting tubular cell growth and enhancing renal function, mainly through the ⁸⁰⁹secretion of regenerative factors such as bone morphogenetic protein-7 and hepatocyte 810 growth factor.⁵⁵ The effectiveness of stem cell therapy in heart repair, particularly in 811 those with elevated levels of inflammation, further underscores the importance of 812 robust stem cells for optimal cardiovascular and renal outcomes. In the glutathione 813 pathway, *DPEP1*⁵⁶, *ORMDL3*, *MRPS21*, and $CPSI^{57,58}$ are crucial for maintaining 814 cellular redox balance and defending against oxidative stress, and they are vital for 815 stroke prevention and kidney function maintenance.^{59,60} Variations in kidney function, 816 reflected by changes in eGFR, can significantly affect glutathione turnover and its 817 protective roles, directly linking renal and cardiovascular health.⁶¹ Our findings suggest 818 that targeted modulation of these key genes could significantly enhance kidney and 819 heart repair and regeneration, thus improving eGFR and decreasing the risk of CVDs.

821 Our study has some limitations. Firstly, the variation in sample sizes across disorders, 822 from 511,634 cases for PAD to 1,500,861 for VTE, restricted our ability to detect 823 pleiotropic effects in less-represented diseases. Future studies with larger, more 824 balanced samples will likely improve our capacity to discern these effects more

825 precisely. Additionally, including subjects with concurrent eGFR abnormalities and 826 CVDs may have introduced bias in our assessment of genetic overlap between these 827 conditions. Our analysis focused on shared genetic variants, excluding rare mutations 828 that could further elucidate the complex genetic relationships involved. Moreover, the 829 concentration on individuals of European ancestry limits the generalizability of our 830 findings to other populations. It is crucial to conduct cross-ancestry follow-up studies to 831 determine whether these results hold across diverse ethnic groups. Overcoming these ⁸³²limitations will require enhancing the diversity of GWAS populations and conducting 833 more extensive experimental validations and cohort analyses.

⁸³⁵**Conclusion**

836 Together, this study has significantly improved our understanding of the genetic basis 837 for the role of eGFR in susceptibility to major CVDs. By identifying crucial genetic 838 components, including key pleiotropic loci and genes such as *L3MBTL3*, *MMP24*, and ⁸³⁹*ABO*, we elucidate potential shared mechanisms that may influence critical biological 840 pathways associated with CVDs, notably stem cell population maintenance and 841 glutathione metabolism. These results provide a better understanding of the genetic ⁸⁴²basis of CVDs and provide a basis for the development of more targeted therapeutic 843 and preventive strategies that could potentially transform cardiovascular care.

⁸⁴⁵**Disclosure**

- 846 All authors declare no competing interests.
-

⁸⁴⁸**Data Statement**

849 The study used only openly available GWAS summary statistics on estimated 850 glomerular filtration rate and six major cardiovascular diseases that have originally 851 been conducted using human data. GWAS summary statistics on eGFR are available at

⁸⁵²https://www.uni-regensburg.de/medizin/epidemiologie-praeventivmedizin/

861

⁸⁶²**Acknowledgements**

863 This study was supported by the Natural Science Foundation of China Excellent Young 864 Scientists Fund (Overseas) (Grant no. K241141101), Guangdong Basic and Applied ⁸⁶⁵Basic Research Foundation for Distinguished Young Scholars (Grant no. ⁸⁶⁶24050000763), Shenzhen Pengcheng Peacock Plan, Shenzhen Basic Research General 867 Projects of Shenzhen Science and Technology Innovation Commission (Grant no. ⁸⁶⁸JCYJ20230807093514029) (To Y.F.), National Natural Science Foundation of China ⁸⁶⁹(Grant no. 82260073); Tianshan Talent Cultivation Program Project of Xinjiang Uygur 870 Autonomous Region (Grant no. 2022TSYCLJ0028) (To Y.Y.), and Center for 871 Computational Science and Engineering at Southern University of Science and 872 Technology. The funder had no role in the design, implementation, analysis, ⁸⁷³interpretation of the data, approval of the manuscript, and decision to submit the

874 manuscript for publication.

875

⁸⁷⁶**Author contributions**

- 877 J.Q., Y. F., Y.Y., J.X., and S.P. conceptualized and supervised this project and wrote the
- 878 manuscript. J.Q., K.Y., and Y.Y. performed the main analyses and wrote the manuscript.
- 879 J.Q., X.Y., Y.Y., L.Z., and Y.L. performed the statistical analysis and assisted with
- 880 interpreting the results. M.C., W.X., and Y.Y. provided expertise in cardiovascular
- 881 biology and GWAS summary statistics. All authors provided intellectual content and
- 882 approved the final version of the manuscript.

883

⁸⁸⁴**Reference**

- 885 1. Roth, G. A. et al. Global, Regional, and National Burden of Cardiovascular 886 Diseases for 10 Causes, 1990 to 2015. Journal of the American College of 887 Cardiology 70, 1-25, doi:10.1016/j.jacc.2017.04.052 (2017).
- ⁸⁸⁸2. Bays, H. E. et al. Ten things to know about ten cardiovascular disease risk 889 factors. American journal of preventive cardiology 5, 100149, 890 doi:10.1016/j.ajpc.2021.100149 (2021).
- 891 3. Popolo, A., Autore, G., Pinto, A. & Marzocco, S. Oxidative stress in patients 892 with cardiovascular disease and chronic renal failure. Free radical research 47, ⁸⁹³346-356, doi:10.3109/10715762.2013.779373 (2013).
- ⁸⁹⁴4. Ammirati, A. L. Chronic Kidney Disease. Revista da Associacao Medica 895 Brasileira (1992) 66Suppl 1, s03-s09, doi:10.1590/1806-9282.66.S1.3 (2020).
- 896 5. Eckardt, K. U. et al. Evolving importance of kidney disease: from subspecialty 897 to global health burden. Lancet (London, England) 382, 158-169, 898 doi:10.1016/s0140-6736(13)60439-0 (2013).
- ⁸⁹⁹6. Visseren, F. L. J. et al. 2021 ESC Guidelines on cardiovascular disease 900 prevention in clinical practice. European journal of preventive cardiology 29, 901 5-115, doi:10.1093/eurjpc/zwab154 (2022).
- ⁹⁰²7. Lees, J. S. et al. Glomerular filtration rate by differing measures, albuminuria 903 and prediction of cardiovascular disease, mortality and end-stage kidney 904 disease. Nat Med 25, 1753-1760, doi:10.1038/s41591-019-0627-8 (2019).
- ⁹⁰⁵8. Manjunath, G. et al. Level of kidney function as a risk factor for cardiovascular 906 outcomes in the elderly. Kidney international 63, 1121-1129, 907 doi:10.1046/j.1523-1755.2003.00838.x (2003).
- ⁹⁰⁸9. Ataklte, F. et al. Association of Mildly Reduced Kidney Function With ⁹⁰⁹Cardiovascular Disease: The Framingham Heart Study. Journal of the American 910 Heart Association 10, e020301, doi:10.1161/jaha.120.020301 (2021).
- 911 10. Graham, S. E. et al. Sex-specific and pleiotropic effects underlying kidney 912 function identified from GWAS meta-analysis. Nature communications 10, 913 1847, doi:10.1038/s41467-019-09861-z (2019).

914 11. Kelly, D. M. et al. Interplay Between Chronic Kidney Disease, Hypertension,

915 and Stroke: Insights From a Multivariable Mendelian Randomization Analysis.

916 Neurology 101, e1960-e1969, doi:10.1212/wnl.0000000000207852 (2023).

- 917 12. Geurts, S. et al. Disentangling the association between kidney function and ⁹¹⁸atrial fibrillation: a bidirectional Mendelian randomization study. International 919 journal of cardiology 355, 15-22, doi:10.1016/j.ijcard.2022.03.004 (2022).
- 920 13. Park, S. et al. Atrial fibrillation and kidney function: a bidirectional Mendelian 921 randomization study. Eur Heart J 42, 2816-2823, 922 doi:10.1093/eurheartj/ehab291 (2021).
- ⁹²³14. Gong, W. et al. Role of the Gut-Brain Axis in the Shared Genetic Etiology ⁹²⁴Between Gastrointestinal Tract Diseases and Psychiatric Disorders: A ⁹²⁵Genome-Wide Pleiotropic Analysis. JAMA psychiatry 80, 360-370, 926 doi:10.1001/jamapsychiatry.2022.4974 (2023).
- 927 15. Stanzick, K. J. et al. Discovery and prioritization of variants and genes for 928 kidney function in >1.2 million individuals. Nature communications 12, 4350, 929 doi:10.1038/s41467-021-24491-0 (2021).
- 930 16. Nielsen, J. B. et al. Biobank-driven genomic discovery yields new insight into 931 atrial fibrillation biology. Nature genetics 50, 1234-1239, 932 doi:10.1038/s41588-018-0171-3 (2018).
- ⁹³³17. Aragam, K. G. et al. Discovery and systematic characterization of risk variants ⁹³⁴and genes for coronary artery disease in over a million participants. Nature 935 genetics 54, 1803-1815, doi:10.1038/s41588-022-01233-6 (2022).
- 936 18. Ghouse, J. et al. Genome-wide meta-analysis identifies 93 risk loci and enables ⁹³⁷risk prediction equivalent to monogenic forms of venous thromboembolism. 938 Nature genetics 55, 399-409, doi:10.1038/s41588-022-01286-7 (2023).
- ⁹³⁹19. Shah, S. et al. Genome-wide association and Mendelian randomisation analysis 940 provide insights into the pathogenesis of heart failure. Nature communications 941 11, 163, doi:10.1038/s41467-019-13690-5 (2020).
- 942 20. van Zuydam, N. R. et al. Genome-Wide Association Study of Peripheral Artery 943 Disease. Circulation. Genomic and precision medicine 14, e002862,

944 doi:10.1161/circgen.119.002862 (2021).

- ⁹⁴⁵21. Mishra, A. et al. Stroke genetics informs drug discovery and risk prediction 946 across ancestries. Nature 611, 115-123, doi:10.1038/s41586-022-05165-3 947 (2022).
- ⁹⁴⁸22. Bulik-Sullivan, B. K. et al. LD Score regression distinguishes confounding 949 from polygenicity in genome-wide association studies. Nature genetics 47, 950 291-295, doi:10.1038/ng.3211 (2015).
- ⁹⁵¹23. Hindley, G. et al. Charting the Landscape of Genetic Overlap Between Mental ⁹⁵²Disorders and Related Traits Beyond Genetic Correlation. The American ⁹⁵³journal of psychiatry 179, 833-843, doi:10.1176/appi.ajp.21101051 (2022).
- ⁹⁵⁴24. Werme, J., van der Sluis, S., Posthuma, D. & de Leeuw, C. A. An integrated ⁹⁵⁵framework for local genetic correlation analysis. Nature genetics 54, 274-282, 956 doi:10.1038/s41588-022-01017-y (2022).
- ⁹⁵⁷25. Darrous, L., Mounier, N. & Kutalik, Z. Simultaneous estimation of ⁹⁵⁸bi-directional causal effects and heritable confounding from GWAS summary 959 statistics. Nature communications 12, 7274, doi:10.1038/s41467-021-26970-w 960 (2021).
- 961 26. Ray, D. & Chatterjee, N. A powerful method for pleiotropic analysis under ⁹⁶²composite null hypothesis identifies novel shared loci between Type 2 Diabetes 963 and Prostate Cancer. PLoS genetics 16, e1009218, 964 doi:10.1371/journal.pgen.1009218 (2020).
- ⁹⁶⁵27. Watanabe, K., Taskesen, E., van Bochoven, A. & Posthuma, D. Functional ⁹⁶⁶mapping and annotation of genetic associations with FUMA. Nature 967 communications 8, 1826, doi:10.1038/s41467-017-01261-5 (2017).
- ⁹⁶⁸28. Kircher, M. et al. A general framework for estimating the relative pathogenicity 969 of human genetic variants. Nature genetics 46, 310-315, doi:10.1038/ng.2892 970 (2014).
- ⁹⁷¹29. Boyle, A. P. et al. Annotation of functional variation in personal genomes using 972 RegulomeDB. Genome research 22, 1790-1797, doi:10.1101/gr.137323.112 973 (2012).

⁹⁷⁴30. Kundaje, A. et al. Integrative analysis of 111 reference human epigenomes.

975 Nature 518, 317-330, doi:10.1038/nature14248 (2015).

- 976 31. Zhu, Z. et al. Integration of summary data from GWAS and eQTL studies 977 bredicts complex trait gene targets. Nature genetics 48, 481-487, 978 doi:10.1038/ng.3538 (2016).
- ⁹⁷⁹32. Wallace, C. A more accurate method for colocalisation analysis allowing for 980 multiple causal variants. PLoS genetics 17, e1009440, 981 doi:10.1371/journal.pgen.1009440 (2021).
- ⁹⁸²33. van der Linden, R. J. et al. Genetic overlap between Alzheimer's disease and 983 blood lipid levels. Neurobiology of aging 108, 189-195, 984 doi:10.1016/j.neurobiolaging.2021.06.019 (2021).
- ⁹⁸⁵34. de Leeuw, C. A., Mooij, J. M., Heskes, T. & Posthuma, D. MAGMA: ⁹⁸⁶generalized gene-set analysis of GWAS data. PLoS computational biology 11, 987 e1004219, doi:10.1371/journal.pcbi.1004219 (2015).
- ⁹⁸⁸35. Gerring, Z. F., Mina-Vargas, A., Gamazon, E. R. & Derks, E. M. E-MAGMA: 989 an eQTL-informed method to identify risk genes using genome-wide 990 association study summary statistics. Bioinformatics (Oxford, England) 37, 991 2245-2249, doi:10.1093/bioinformatics/btab115 (2021).
- ⁹⁹²36. Gusev, A. et al. Integrative approaches for large-scale transcriptome-wide 993 ssociation studies. Nature genetics 48, 245-252, doi:10.1038/ng.3506 (2016).
- ⁹⁹⁴37. Zhou, Y. et al. Metascape provides a biologist-oriented resource for the analysis 995 of systems-level datasets. Nature communications 10, 1523, 996 doi:10.1038/s41467-019-09234-6 (2019).
- ⁹⁹⁷38. Levy, D. et al. Genome-wide association study of blood pressure and 998 hypertension. Nature genetics 41, 677-687, doi:10.1038/ng.384 (2009).
- ⁹⁹⁹39. Yamada, Y. et al. Identification of 13 novel susceptibility loci for early-onset ¹⁰⁰⁰myocardial infarction, hypertension, or chronic kidney disease. International 1001 journal of molecular medicine 42, 2415-2436, doi:10.3892/ijmm.2018.3852 1002 (2018).
- ¹⁰⁰³40. Liu, C. et al. STUB1 is acetylated by KAT5 and alleviates myocardial

- 1004 ischemia-reperfusion injury through LATS2-YAP- β -catenin axis. 1005 Communications biology 7, 396, doi:10.1038/s42003-024-06086-9 (2024).
- ¹⁰⁰⁶41. Hishikawa, A. et al. DNA repair factor KAT5 prevents ischemic acute kidney 1007 injury through glomerular filtration regulation. iScience 24, 103436, 1008 doi:10.1016/j.isci.2021.103436 (2021).
- ¹⁰⁰⁹42. Cano, E. A. et al. Association between ABO Blood Groups and Type 2 Diabetes ¹⁰¹⁰Mellitus: A Meta-Analysis. Curr Diabetes Rev 19, e270422204139, 1011 doi:10.2174/1573399818666220427124448 (2023).
- 1012 43. Yuan, S., Bruzelius, M. & Larsson, S. C. Causal effect of renal function on 1013 venous thromboembolism: a two-sample Mendelian randomization ¹⁰¹⁴investigation. Journal of thrombosis and thrombolysis 53, 43-50, 1015 doi:10.1007/s11239-021-02494-4 (2022).
- ¹⁰¹⁶44. Watanabe, H. et al. Close bidirectional relationship between chronic kidney 1017 disease and atrial fibrillation: the Niigata preventive medicine study. American ¹⁰¹⁸heart journal 158, 629-636, doi:10.1016/j.ahj.2009.06.031 (2009).
- ¹⁰¹⁹45. Kim, J. J. et al. Identification of B-cell-related HSPG2 and CDSN as ¹⁰²⁰susceptibility loci for Kawasaki disease. Human immunology 84, 567-570, 1021 doi:10.1016/j.humimm.2023.07.001 (2023).
- ¹⁰²²46. Newburger, J. W. et al. Diagnosis, treatment, and long-term management of ¹⁰²³Kawasaki disease: a statement for health professionals from the Committee on ¹⁰²⁴Rheumatic Fever, Endocarditis and Kawasaki Disease, Council on ¹⁰²⁵Cardiovascular Disease in the Young, American Heart Association. Circulation 1026 110, 2747-2771, doi:10.1161/01.Cir.0000145143.19711.78 (2004).
- ¹⁰²⁷47. Sallinen, R. et al. Association of the SLC22A1, SLC22A2, and SLC22A3 genes ¹⁰²⁸encoding organic cation transporters with diabetic nephropathy and 1029 hypertension. Annals of medicine 42, 296-304, 1030 doi:10.3109/07853891003777109 (2010).
- ¹⁰³¹48. Garcia-Fernandez, N. et al. Matrix Metalloproteinases in Diabetic Kidney ¹⁰³²Disease. Journal of clinical medicine 9, doi:10.3390/jcm9020472 (2020).
- ¹⁰³³49. Chen, S., Chen, L. & Jiang, H. Prognosis and risk factors of chronic kidney

¹⁰³⁴disease progression in patients with diabetic kidney disease and non-diabetic

1035 kidney disease: a prospective cohort CKD-ROUTE study. Renal failure 44,

1036 1309-1318, doi:10.1080/0886022x.2022.2106872 (2022).

- ¹⁰³⁷50. Zhang, H., Mooney, C. J. & Reilly, M. P. ABO Blood Groups and 1038 Cardiovascular Diseases. Int J Vasc Med 2012, 641917, 1039 doi:10.1155/2012/641917 (2012).
- ¹⁰⁴⁰51. Wang, M. et al. Associations of ABO blood type and galactose-deficient 1041 immunoglobulin A1 with adverse outcomes in patients with IgA nephropathy. ¹⁰⁴²Nephrology, dialysis, transplantation : official publication of the European ¹⁰⁴³Dialysis and Transplant Association - European Renal Association 36, 288-294, 1044 doi:10.1093/ndt/gfz171 (2021).
- ¹⁰⁴⁵52. Porlan, E. et al. MT5-MMP regulates adult neural stem cell functional 1046 quiescence through the cleavage of N-cadherin. Nature cell biology 16, 629-638, 1047 doi:10.1038/ncb2993 (2014).
- ¹⁰⁴⁸53. Wilson, N. K. et al. Combined Single-Cell Functional and Gene Expression ¹⁰⁴⁹Analysis Resolves Heterogeneity within Stem Cell Populations. Cell stem cell 1050 16, 712-724, doi:10.1016/j.stem.2015.04.004 (2015).
- 1051 54. Coulter, M. E. et al. The ESCRT-III Protein CHMP1A Mediates Secretion of 1052 Sonic Hedgehog on a Distinctive Subtype of Extracellular Vesicles. Cell reports ¹⁰⁵³24, 973-986.e978, doi:10.1016/j.celrep.2018.06.100 (2018).
- 1054 55. Hopkins, C., Li, J., Rae, F. & Little, M. H. Stem cell options for kidney disease. 1055 J Pathol 217, 265-281, doi:10.1002/path.2477 (2009).
- ¹⁰⁵⁶56. Strauer, B. E. & Steinhoff, G. 10 years of intracoronary and intramyocardial 1057 bone marrow stem cell therapy of the heart: from the methodological origin to ¹⁰⁵⁸clinical practice. Journal of the American College of Cardiology 58, 1095-1104, 1059 doi:10.1016/j.jacc.2011.06.016 (2011).
- ¹⁰⁶⁰57. Lau, A. et al. Dipeptidase-1 governs renal inflammation during ischemia 1061 reperfusion injury. Science advances 8, eabm0142, 1062 doi:10.1126/sciadv.abm0142 (2022).
- ¹⁰⁶³58. Wu, J. et al. Regulation of the urea cycle by CPS1 O-GlcNAcylation in response

1064 to dietary restriction and aging. Journal of molecular cell biology 14, 1065 doi:10.1093/jmcb/mjac016 (2022).

- ¹⁰⁶⁶59. Matuz-Mares, D., Riveros-Rosas, H., Vilchis-Landeros, M. M. & V ^á ¹⁰⁶⁷zquez-Meza, H. Glutathione Participation in the Prevention of Cardiovascular 1068 Diseases. Antioxidants (Basel, Switzerland) 10, doi:10.3390/antiox10081220 1069 (2021).
- ¹⁰⁷⁰60. Bajic, V. P. et al. Glutathione "Redox Homeostasis" and Its Relation to 1071 Cardiovascular Disease. Oxidative medicine and cellular longevity 2019, 1072 5028181, doi:10.1155/2019/5028181 (2019).
- ¹⁰⁷³61. Hinchman, C. A. & Ballatori, N. Glutathione-degrading capacities of liver and 1074 kidney in different species. Biochemical pharmacology 40, 1131-1135, 1075 doi:10.1016/0006-2952(90)90503-d (1990).

1076

1077

¹⁰⁷⁸**Figure 1: Schematic diagram of the analysis of genetic associations between glomerular** ¹⁰⁷⁹**filtration rate and six major cardiovascular diseases in this study.**

¹⁰⁸⁰We analyzed the most comprehensive GWAS summary statistics to investigate the shared genetic 1081 architecture and potential mechanisms between eGFR and CVDs. First, the shared genetic basis was 1082 determined by quantifying global and local genetic correlations and exploring the global genetic 1083 overlap. Then, their two genetic pleiotropy were analyzed to investigate the shared genetic

¹⁰⁹⁴**Figure 2: Genetic overlap between estimated glomerular filtration rate and six major** ¹⁰⁹⁵**cardiovascular diseases exceeds genome-wide genetic correlation.**

1096 Genetic overlap and local genetic correlation between eGFR and six major CVDs investigated by 1097 MiXeR and LAVA. a: MiXeR Venn diagrams showing common and unique effect trait variants

¹¹¹²**Figure 3: Inference of causal relationship between estimated glomerular filtration rate and six** ¹¹¹³**major cardiovascular diseases.**

1114 Forest plots of the causal relationship between eGFR and six major CVDs using the LHC-MR 1115 method. a: indicates the estimated causal relationship of eGFR on CVDs. b: indicates the estimated 1116 causal relationship of CVDs on eGFR. Circles indicate odds ratio (OR) estimates, and error bars 1117 indicate 95% confidence intervals. OR > 1 indicates a positive association, and OR < 1 indicates a 1118 negative association. eGFR, estimated glomerular filtration rate; AF, atrial fibrillation; CAD, 1119 coronary artery disease; VTE, venous thromboembolism; HF, heart failure; PAD, peripheral arterial 1120 disease.

¹¹²²**Figure 4: Manhattan plot of PLACO results for estimated glomerular filtration rate and six** ¹¹²³**major cardiovascular diseases.**

1124 Manhattan plots reflect chromosomal position (x-axis) and negative log10-transformed *P*-values 1125 (y-axis) for each SNP. Horizontal lines indicate genome-wide significant P-values -log10 (5×10^{-8}). 1126 The r^2 threshold for defining independent significant SNPs was set to 0.2, and the maximum 1127 distance between LD blocks merged into one locus was set to 500 kb. *P*-values were derived using ¹¹²⁸GWAS multi-trait analysis in discovery studies, and independent genome-wide significant 1129 associations with the smallest *P*-values (top SNPs) are circled in colored circles. Only SNPs that 1130 were common in all summary statistics were included. Labels are chromosomal regions where 1131 genomic risk loci with strong colocalization evidence (PP.H4 > 0.7) are located. eGFR, estimated 1132 glomerular filtration rate; AF, atrial fibrillation; CAD, coronary artery disease; VTE, venous 1133 thromboembolism; HF, heart failure; PAD, peripheral arterial disease.

1134
1135 ¹¹³⁵**Figure 5: The overall situation of the pleiotropy association between estimated glomerular** ¹¹³⁶**filtration rate and six major cardiovascular diseases**

1137 Based on the polygenic nature of the Mixer results, we separated the pleiotropic association between ¹¹³⁸eGFR and CVDs into two network diagrams, showing the pleiotropic loci and genes identified in 1139 the six trait pairs. a: The circular dendrogram is centered on eGFR (inner circle) and branches out 1140 for the three CVDs (second circle, AF, VTE, and PAD). These three trait pairs show 91 pleiotropic 1141 loci (third circle) corresponding to 159 pleiotropic genes (outer circle). b: The circular dendrogram 1142 is centered on eGFR (the inner circle) and branches out for the three CVDs (second circle, CAD, HF, 1143 and stroke). Another three trait pairs show 80 pleiotropic loci (third circle) corresponding to 153 1144 pleiotropic genes (outer circle). For trait pairs with three or more pleiotropic genes, we only show 1145 the top three pleiotropic genes according to priority, and these genes show statistical priority decay 1146 in a clockwise direction. For example, eGFR-AF-12q24.31-CCDC92 and ¹¹⁴⁷eGFR-AF-12q24.31-ZNF664 indicate that 12q24.31 is a shared locus for this pair of specific 1148 diseases involving CCDC92 and ZNF664. eGFR, estimated glomerular filtration rate; AF, atrial ¹¹⁴⁹fibrillation; CAD, coronary artery disease; VTE, venous thromboembolism; HF, heart failure; PAD, 1150 peripheral arterial disease.